Ryan Allen
Community Member
Last active: 4/25/2016


None provided


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Dysfunctional high-density lipoproteins in children with chronic kidney disease. Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM, Vickers KC, Yancey PG, Linton MF, Fazio S, Kon V (2015) Metabolism 64(2): 263-73
    › Primary publication · 25467845 (PubMed) · PMC4277938 (PubMed Central)
  2. Coenzyme Q10 increases cholesterol efflux and inhibits atherosclerosis through microRNAs. Allen RM, Vickers KC (2014) Arterioscler Thromb Vasc Biol 34(9): 1795-7
    › Primary publication · 25142877 (PubMed) · PMC4142520 (PubMed Central)
  3. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. Goedeke L, Salerno A, Ramírez CM, Guo L, Allen RM, Yin X, Langley SR, Esau C, Wanschel A, Fisher EA, Suárez Y, Baldán A, Mayr M, Fernández-Hernando C (2014) EMBO Mol Med 6(9): 1133-41
    › Primary publication · 25038053 (PubMed) · PMC4197861 (PubMed Central)
  4. Perilipin-5 is regulated by statins and controls triglyceride contents in the hepatocyte. Langhi C, Marquart TJ, Allen RM, Baldán A (2014) J Hepatol 61(2): 358-65
    › Primary publication · 24768901 (PubMed) · PMC4104237 (PubMed Central)
  5. Control of very low-density lipoprotein secretion by N-ethylmaleimide-sensitive factor and miR-33. Allen RM, Marquart TJ, Jesse JJ, Baldán A (2014) Circ Res 115(1): 10-22
    › Primary publication · 24753547 (PubMed) · PMC4108429 (PubMed Central)
  6. Impaired liver regeneration in Ldlr-/- mice is associated with an altered hepatic profile of cytokines, growth factors, and lipids. Pauta M, Rotllan N, Vales F, Fernandez-Hernando A, Allen RM, Ford DA, Marí M, Jiménez W, Baldán A, Morales-Ruiz M, Fernández-Hernando C (2013) J Hepatol 59(4): 731-7
    › Primary publication · 23712050 (PubMed) · PMC4145584 (PubMed Central)
  7. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, Ford DA, Baldán A (2012) EMBO Mol Med 4(9): 882-95
    › Primary publication · 22767443 (PubMed) · PMC3491822 (PubMed Central)
  8. Mir-33 regulates cell proliferation and cell cycle progression. Cirera-Salinas D, Pauta M, Allen RM, Salerno AG, Ramírez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion MA, Morales-Ruiz M, Suarez Y, Baldan Á, Esplugues E, Fernández-Hernando C (2012) Cell Cycle 11(5): 922-33
    › Primary publication · 22333591 (PubMed) · PMC3323796 (PubMed Central)
  9. miR-33 links SREBP-2 induction to repression of sterol transporters. Marquart TJ, Allen RM, Ory DS, Baldán A (2010) Proc Natl Acad Sci U S A 107(27): 12228-32
    › Primary publication · 20566875 (PubMed) · PMC2901433 (PubMed Central)